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Abstract This study was conducted on human Jurkat T-cells
to investigate the role of depletion of intracellular Ca2+ stores in
the phosphorylation of two mitogen-activated protein kinases
(MAPKs), i.e. extracellular signal-regulated kinase (ERK) 1
and ERK2, and their modulation by a polyunsaturated fatty
acid, docosahexaenoic acid (DHA). We observed that thapsigar-
gin (TG) stimulated MAPK activation by store-operated calci-
um (SOC) in£ux via opening of calcium release-activated cal-
cium (CRAC) channels as tyrphostin-A9, a CRAC channel
blocker, and two SOC in£ux inhibitors, econazole and SKF-
96365, diminished the action of the former. TG-stimulated
ERK1/ERK2 phosphorylation was also diminished in bu¡er con-
taining EGTA, a calcium chelator, further suggesting the impli-
cation of calcium in£ux in MAPK activation in these cells.
Moreover, TG stimulated the production of diacylglycerol
(DAG) by activating phospholipase D (PLD) as propranolol
(PROP) (a PLD inhibitor), but not U73122 (a phospholipase
C inhibitor), inhibited TG-evoked DAG production in these
cells. DAG production and protein kinase C (PKC) activation
were involved upstream of MAPK activation as PROP and
GF109203X, a PKC inhibitor, abolished the action of TG on
ERK1/ERK2 phosphorylation. Furthermore, DHA seems to act
by inhibiting PKC activation as this fatty acid diminished TG-
and phorbol 12-myristate 13-acetate-induced ERK1/ERK2
phosphorylation in these cells. Together these results suggest
that Ca2+ in£ux via CRAC channels is implicated in PLD/
PKC/MAPK activation which may be a target of physiological
agents such as DHA.
= 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
It has been established that T-cell activation via T-cell re-
ceptors is associated with activation of phospholipase C
(PLC) Q1 which cleaves phosphatidylinositol 4,5-bisphosphate
into inositol trisphosphate (IP3) and diacylglycerol (DAG) [1].
Hence, binding of IP3 to its receptor on the endoplasmic
reticulum (ER) releases Ca2þ whereas DAG activates protein
kinase C (PKC) [1]. According to the capacitative model of
calcium homeostasis [2], there is a biphasic rise in the intra-
cellular concentration of free Ca2þ ([Ca2þ]i), hence a calcium
release from ER stores is followed by Ca2þ in£ux across the
plasma membrane [3]. The rise in [Ca2þ]i constitutes an essen-
tial triggering signal for T-cell di¡erentiation and proliferation
[4]. Raising [Ca2þ]i has been found to increase the activity of a
transcription factor, the nuclear factor of activated T-cells,
which, in turn, results in the expression of the lacZ gene in
transfected murine T-cells [5]. Calcium oscillations with re-
peated spikes for a period of 100 s are su⁄cient to activate
the transcriptional factors in human T-cells [6]. Following the
depletion of intracellular Ca2þ stores, the re¢lling of these
stores is brought about by opening of store-operated Ca2þ
(SOC) channels [2]. SOC channels are modulated by PKC
or DAG [7^9]. SOC in£ux is also brought about by opening
of Ca2þ release-activated Ca2þ (CRAC) channels in human
T-cells [10]. It has been reported that activation of these chan-
nels is accelerated by a soluble calcium in£ux factor which is
released into the extracellular medium during SOC depletion
in Jurkat T-cells [11].
Phospholipase D (PLD) hydrolyzes phospholipids to pro-
duce phosphatidic acid (PA) that gives rise to DAG [12]. PLD
activity is regulated by many factors [13] and so we investi-
gated whether an increase in free intracellular calcium via
SOC activated PLD and mitogen-activated protein kinases
(MAPKs) in Jurkat T-cells.
It has been shown that diets enriched with n-6 polyunsatu-
rated fatty acids (PUFAs) stimulate the growth of di¡erent
cell types and promote metastasis whereas diets containing n-3
PUFAs inhibit cell growth and exert immunosuppressive ef-
fects [14,15]. We have recently shown that docosahexaenoic
acid (DHA) inhibits MAPK activation in Jurkat T- cells
[16,17] and 3T3 ¢broblasts [18,19]. We were tempted to ascer-
tain whether SOC in£ux-stimulated MAPK activation can be
further inhibited by this fatty acid.
2. Materials and methods
2.1. Chemicals
Anti-phosphorylated MAPK (extracellular signal-regulated kinase
(ERK) 1/ERK2) antibodies and U0126 were obtained from Ozyme
(Saint Quentin, France). GF109203X, tyrphostin A9 (TA9) and SKF-
96365 were obtained from Calbiochem, France. [Q-32P]ATP (4000 Ci/
mmol) and [3H]palmitic acid (57 Ci/mmol) were purchased from
Amersham, France. Fura-2/AM was obtained from Molecular Probes
0014-5793 / 04 / $30.00 J 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0014-5793(04)00361-8
*Corresponding author. Fax: (33)-3-80 39 63 30.
E-mail address: naim.khan@u-bourgogne.fr (N.A. Khan).
Abbreviations: [Ca2þ]i, intracellular free calcium concentration;
CRAC, Ca2þ release-activated Ca2þ ; DAG, diacylglycerol; DHA,
docosahexaenoic acid; ERK, extracellular signal-regulated kinase;
MAPK, mitogen-activated protein kinase; PKC, protein kinase C;
PLC, phospholipase C; PLD, phospholipase D; PMA, phorbol 12-
myristate 13-acetate; PROP, propranolol; PUFA, polyunsaturated
fatty acid; SOC, store-operated calcium; TA9, tyrphostin A9
FEBS 28302 8-4-04
FEBS 28302 FEBS Letters 564 (2004) 177^182
(Eugene, OR, USA). All other chemicals including phorbol 12-myr-
istate 13-acetate (PMA), DHA (22:6 n-3), nifedipine, g-conotoxin and
econazole were procured from Sigma (St. Louis, MO, USA).
2.2. Cell culture and preparation of extracts
The Jurkat T-cells were routinely cultured in RPMI 1640 medium
supplemented with L-glutamine and 10% fetal calf serum at 37‡C in a
humidi¢ed chamber containing 95% air and 5% CO2. Cell viability
was assessed by trypan blue exclusion test. Cell numbers were deter-
mined by hemocytometer.
DHA was dissolved in ethanol at a ¢nal concentration of 0.01%
(v/v). Prior to determining the MAPK activation, cells were incubated
for 6 h in the RPMI 1640 medium without serum. Cells were then
suspended in bu¡er containing NaCl, 110 mM; KCl, 5.4 mM;
NaHCO3, 25 mM; MgCl2, 0.8 mM; KH2PO4, 0.4 mM; HEPES, 20
mM; NaHPO4, 0.33 mM; CaCl2, 1.2 mM. To make a calcium-free
bu¡er, CaCl2 was replaced in this bu¡er with EGTA, 2.4 mM. Jurkat
T-cells (5U106/ml) were incubated or not for 5 min in the presence of
n-3 PUFA, DHA (20 WM), and then stimulated with thapsigargin
(TG) (500 nM) for 20 min. After incubation at 37‡C, cells were lysed
with 50 Wl of bu¡er containing the following: HEPES, 20 mM pH
7.3; EDTA, 1 mM; EGTA, 1 mM; NaCl, 0.15 mM; Triton X-100
1%; glycerol 10%; phenylmethylsulfonyl £uoride, 1 mM; sodium or-
thovanadate, 2 mM; anti-protease cocktail (2 Wl in 1 ml of bu¡er).
After centrifugation (13 000Ug ; 1 min), cell lysates were used imme-
diately, or stored at 380‡C. The protein contents were determined
with Folin reagent.
2.3. Western blot detection of phosphorylated ERK1/ERK2
Denatured proteins (20 Wg) were separated on sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis (10%), transferred to polyvi-
nylidene di£uoride membranes and immunodetection was performed
by using anti-phosphorylated ERK1/ERK2 antibodies. After incuba-
tion of membranes with horseradish peroxidase-conjugated goat anti-
rabbit secondary antibodies at 1:2000, peroxidase activity was de-
tected using ECL reagents (Amersham, France).
2.4. Measurement of DAG production
Jurkat T-cells were serum-starved during 6 h then preincubated for
15 min in the presence of inhibitors, followed by 20 min incubation
with TG (500 nM). Incubation was stopped by the addition of meth-
anol and DAGs were extracted ¢ve times with hexane and quantita-
tively converted to [32P]PA as described elsewhere [20]. Brie£y, the
dried lipid extract was solubilized in 20 Wl of n-octyl-L-D-glucopyrano-
side and cardiolipin solution (7.5% n-octyl-L-D-glucopyranoside, 5 mM
cardiolipin in 1 mM DETAPAC) and incubated for 5^15 min at room
temperature with DAG kinase in the presence of [32P]ATP (speci¢c
activity 100 000^500 000 cpm/nmol). The reaction was allowed to pro-
ceed at 25‡C for 30 min. The resulting PA was then extracted and
separated by thin-layer chromatography (TLC) (chloroform/metha-
nol/acetic acid, 65:15:5, v/v). The area corresponding to PA was
scraped o¡ and the radioactivity was determined by liquid scintillation
counting. In these experiments, tritiated sn-1,2-dioleoylglycerol was
used as an internal standard to monitor conversion and recovery
which was routinely s 90% over the entire concentration range
(data not shown). TLC analysis of DAG kinase reaction products
demonstrated that 99% of the radioactivity was PA.
2.5. Determination of PLD activity
PLD activity was determined by measuring the production of phos-
phatidylbutanol (Pbut) as described elsewhere [21]. In brief, Jurkat
T-cells (10U106 cells/ml) were incubated during 16 h in the presence
of 5 WCi/ml of [3H]palmitic acid (57 Ci/mmol) diluted with RPMI
medium without serum but containing 0.2% bovine serum albumin
(w/v) (RPMI-BSA). The cells were washed two times with RPMI-BSA
and incubated for 30 min in fresh medium containing butan-1-ol
(0.5%, v/v) with or without propranolol (PROP), EGTA or the
SOC in£ux inhibitors, econazole and SKF-96365, before further acti-
vation by TG for 20 min. The reaction was stopped by adding 2 ml of
methanol and chloroform, and 2 M NaCl plus 0.01 N HCl were
added to yield a ¢nal methanol/chloroform/aqueous phase, 1:1:0.9
(v/v). The organic phase was separated by TLC in the upper phase
of isooctane/ethyl acetate/acetic acid/water (10:65:15:50; v/v), then
the radiolabeled areas corresponding to Pbut were scraped o¡ and
the radioactivity was measured by liquid scintillation counting.
2.6. Measurement of Ca2+ signalling
The cells (2U106/ml) were washed with phosphate-bu¡ered saline
(PBS), pH 7.4. The composition of PBS was as follows (in mM):
KH2PO4, 3.5; Na2HPO4, 17.02; NaCl, 136. The cells were then in-
cubated with Fura-2/AM (1 WM) for 60 min at 37‡C in loading bu¡er
which contained the following (in mM): NaCl, 110; KCl, 5.4;
NaHCO3, 25; MgCl2, 0.8; KH2PO4, 0.4; HEPES, 20; Na2HPO4,
0.33; CaCl2, 1.2 and the pH was adjusted to 7.4.
After loading, the cells were washed three times (2000Ug, 10 min)
and remained suspended in the identical bu¡er. [Ca2þ]i was measured
according to Grynkiewicz et al. [22]. The £uorescence intensities were
measured in the ratio mode in a PTI spectro£uorometer at 340 nm
and 380 nm (excitation ¢lters) and 510 nm (emission ¢lter). The cells
were continuously stirred throughout the experiment. The test mole-
cules were added into the cuvettes in small volumes with no interrup-
tions in recordings. The [Ca2þ]i was calculated using the following
equation: [Ca2þ]i =KdU(R3Rmin)/(Fmax3F)U(Sf2/Sb2). A value of
224 nM for Kd was added into the calculations. Rmax and Rmin values
were obtained by addition of ionomycin (5 WM) and MnCl2 (2 mM),
respectively. All the experiments were performed at 37‡C.
2.7. Statistical analysis
Statistical analysis of data was carried out using Statistica (version
4.1, Statsoft, Paris, France). The signi¢cance of the di¡erences be-
tween mean values was determined by one way analysis of variance,
followed by a least-signi¢cant-di¡erence test.
3. Results and discussion
The present study was conducted to assess the role of SOC
in£ux in the phosphorylation of ERK1/ERK2 in Jurkat
T-cells. To induce SOC in£ux, we employed TG, an inhibitor
of Ca2þ-ATPase of ER [23].
In the present study, we employed BAPTA, an agent that
Fig. 1. E¡ect of calcium £uxes on TG-stimulated ERK1/ERK2 acti-
vation. Jurkat T-cells (5U106 cells/ml), prior to determining ERK1/
ERK2 phosphorylation, were incubated during 6 h in RPMI 1640
medium without serum. After incubation at 37‡C, MAPK assays
were performed as described in Section 2. A: Intracellular and
extracellular Ca2þ concentrations were depleted, respectively, by
BAPTA, 1 WM and EGTA, 2.4 mM, by incubating cells for 10 min.
Cells were also treated with econazole (Eco), 15 WM and SKF-
96365 (SKF), 30 WM for 20 min. Later on, the cells were treated or
not (control) with TG, 500 nM, for 20 min. B: Cells were pre-
treated or not for 15 min with calcium channel blockers (nifedipine,
1 WM; g-conotoxin, 1 WM) and then were further treated or not
(control) with TG, 500 nM, for 20 min. In 0% Ca2þ medium, CaCl2
was replaced by EGTA, 2.4 mM. Later on, these cells were stimu-
lated or not (control) with TG, 500 nM, for 20 min. C: The same
treatments as in B except the cells were treated with PMA.
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completely chelates [Ca2þ]i. In the presence of BAPTA, TG-
recruited intracellular calcium will rapidly bind to this agent
and, therefore, SOC in£ux will not take place. Fig. 1A shows
that TG-stimulated ERK1/ERK2 phosphorylation was signif-
icantly diminished in the presence of BAPTA. TG again failed
to stimulate MAPK activation in the presence of EGTA, an
agent that chelates extracellular calcium (Fig. 1A). These ob-
servations suggest that this is not a release of calcium from
the intracellular pool but rather the calcium in£ux which is
implicated in the phosphorylation of MAPKs in Jurkat
T-cells. In order to probe the role of calcium channels, impli-
cated in TG-stimulated MAPK activation, we employed
g-conotoxin and nifedipine, the blockers of L-type and
N-type calcium channels respectively. We observed that the
incubation of Jurkat T-cells in the presence of g-conotoxin
and nifedipine failed to curtail the TG-stimulated MAPK ac-
tivation (Fig. 1B). The failure of the inhibition of MAPK
activation by g-conotoxin and nifedipine corroborates our
previous observations in which we have demonstrated that
these channels are not implicated in calcium in£ux in Jurkat
T-cells [24]. Similarly, these calcium channel blockers could
not a¡ect the PMA-induced MAPK phosphorylation (Fig.
1C). Since we employed TA9, and econazole and SKF-
96365, SOC inhibitors (see below), the use of g-conotoxin
and nifedipine seemed mandatory as controls.
It has been shown that SOC in£ux in human T-cells may
take place by opening of CRAC channels. The CRAC chan-
nels were originally described in mast cells [25]. Human Jurkat
T-cells express nearly 10 000 CRAC channels per cell [26,27].
The CRAC channels are not opened directly by depolariza-
tion, IP3 or IP4 [28]. The depletion-activated CRAC channels
underline mitogenic Ca2þ in£ux in T-cells. In order to ascer-
tain the role of these channels, we used TA9, an inhibitor of
CRAC channels [10], and econazole and SKF-96365, inhibi-
tors of SOC in£ux [29,30]. Furthermore, TA9, and econazole
and SKF-96365 diminished the action of TG on the activation
of MAPK (Fig. 1A,B). In 0% Ca2þ medium, the calcium
channel blockers could not a¡ect the TG-stimulated ERK1/
ERK2 phosphorylation in these cells. These observations sug-
gest that SOC in£ux via opening of CRAC channels is impli-
cated in the phosphorylation of ERK1/ERK2 in Jurkat
T-cells. Our report is in close agreement with the observations
of Atherfold et al. [31] who have shown that calcium in£ux,
evoked by calcium ionophores such as A23187, induces
ERK1/ERK2 activation in human primary and Jurkat T-cells.
Though PMA also induced MAPK activation, its action was
not inhibited by TA9 in Jurkat T-cells (Fig. 1C) and it is due
to the fact that PMA does not activate MAPKs by inducing
calcium in£ux but rather it acts directly on the Zn-butter£y
domain of PKC [32].
It has been established that MAPK activation in Jurkat
T-cells is coupled to PKC activation via Raf-1 upstream of
MAPK/ERK kinase (MEK) [33]. Hence, we were interested to
ascertain whether TG-stimulated MAPK activation is coupled
to the PKC/MEK pathway. We therefore employed U0126,
an inhibitor of MEK, and GF109203X, a PKC inhibitor. Fig.
2 shows that U0126 and GF109203X completely abolished the
TG-stimulated MAPK activation in Jurkat T-cells. On the
other hand, TG did not exert additive e¡ects on PMA-in-
duced ERK1/ERK2 activation in these cells (Fig. 2), suggest-
ing that TG and PMA exert their actions via the same path-
way. The failure to exert an additive response by TG and
PMA is not due to saturation of MAPK activation by either
of the agents as ionomycin in the presence of PMA does exert
an additive response in the same experimental conditions (Fig.
2). Hence, the scanner provided the following blot intensities:
200T 10% fold increases in PMA plus ionomycin, 100T 5%
fold increases in PMA, 100T6% fold increases in PMA plus
TG as compared to TG alone (100%).
DAG is mainly generated through the actions of PLC and
PLD [32]. In order to probe the role of PLC and PLD, we
used U73122, a PLC inhibitor, and PROP, a PLD inhibitor.
Fig. 2 shows that only PROP, but not U73122, inhibited
the activation of ERK1/ERK2, stimulated by TG in Jurkat
T-cells. We also measured the production of DAG, evoked by
TG. We observed that TG stimulated DAG production after
1 min of stimulation which was sustained for 20 min (Fig. 3,
inset). Furthermore, as expected, PROP, but not U73122, in-
hibited TG-induced DAG production (Fig. 3a). Since PROP
is an inhibitor of PA hydrolase, these observations suggest
that DAG production by TG via PA is catalyzed by the
PLD/PA pathway in these cells. We further detected the
PLD activity by measuring the production of Pbut catalyzed
by transphosphatidylation in the presence of butan-1-ol. Fig.
3b shows that the production of Pbut was increased by TG.
Altogether, these observations suggest that TG-stimulated
MAPK activation is dependent on PLD signalling involving
DAG production in Jurkat T-cells.
How DAG is produced by TG in Jurkat T-cells is not well
understood. However, it is possible that TG-stimulated SOC
in£ux via CRAC channels may contribute to PLD activation.
It is noteworthy that EGTA, TA9, econazole and SKF-96365
Fig. 2. E¡ect of inhibitors of PKC, PLC, MEK and PLD on TG-
stimulated ERK1/ERK2 phosphorylation. Jurkat T-cells (5U106
cells/ml), prior to determining the ERK1/ERK2 phosphorylation,
were incubated during 6 h in RPMI 1640 medium without serum.
To evaluate the mechanism of action of TG, cells were pretreated
or not for 20 min with U73122, 3 WM, GF109203X, 500 nM,
PROP, 50 WM or U0126, 10 WM and then stimulated for 20 min
with TG, 500 nM, PMA, 200 nM, PMA, 200 nM plus ionomycin
(Iono), 500 nM. After incubation at 37‡C, cells were lysed and the
detection of phosphorylated MAPKs was performed as described in
Section 2.
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signi¢cantly inhibited TG-stimulated production of DAG and
Pbut in Jurkat T-cells (Fig. 3a,b). Our observations are sup-
ported by the ¢ndings of Walter et al. [34] who have reported
the role of PLD during TG-induced calcium store depletion in
vascular smooth muscle cells. Singh et al. [35] have also dem-
onstrated that agents like ionomycin that increase intracellular
calcium do induce PLD basal activity in UMR-106 cells. In
this study, EGTA and BAPTA signi¢cantly attenuated the
PLD activation. The e¡ects of calcium on PLD activation
seem speci¢c since A23187 triggered an increase both in cal-
cium concentrations and in PLD activation in PLD1- and
PLD2-overexpressing, but not in control, Sf9 cells [36].
Though PLC activation and, consequently, DAG production
by TG have also been reported in human peripheral blood
lymphocytes [37], TG-stimulated DAG production via PLC
and PLD seems to be a cell-speci¢c phenomenon and Jurkat
T-cells may di¡er from freshly isolated human T-cells from
the point of view of regulation of several cell functions.
DHA belongs to the n-3 PUFAs which have been shown to
exert immunosuppressive actions in vitro and in vivo [14].
DHA has been shown to induce increases in [Ca2þ]i [24]
and DAG containing this fatty acid is implicated in the mod-
ulation of PKC [38] and MAPK activation [39]. In the present
study, we observed that DHA diminished the TG-induced
MAPK activation in Jurkat T-cells (Fig. 4A). The action of
DHA seems speci¢c as DHA-methyl ester failed to curtail the
Fig. 3. E¡ect of inhibitors of PLC and PLD on TG-stimulated [14C]DAG and [3H]Pbut production. Jurkat T-cells (5U106 cells/ml) were incu-
bated during 6 h in RPMI 1640 medium without serum. a: The cells were incubated for 20 min with U73122, 3 WM, PROP, 50 WM, TA9, 10
WM, EGTA, 2.4 mM, econazole (Eco), 15 WM, and SKF-96365 (SKF), 30 WM. Cells were treated with TG, 500 nM, in the presence of
[32P]ATP. Treatment was arrested with cold methanol. Then, DAG was extracted and quanti¢ed as described in Section 2. Results are given as
CPM percentage of control in the lipid extract and represent meanTS.E.M. of three separate experiments, each in duplicate. Data are signi¢-
cantly di¡erent as compared to TG-treated (none) (*P6 0.001) and control cells (**P6 0.001). Inset: Cells were treated with TG, 500 nM, for
indicated times. b: Jurkat T-cells (10U106 cells/ml) were incubated during 16 h in the presence of 5 WCi/ml of [3H]palmitic acid diluted with
RPMI 1640 medium without serum containing 0.2% BSA. The cells, containing butan-1-ol (0.5%), were then preincubated or not during 20
min with PROP, 50 WM, TA9, 10 WM, EGTA, 2.4 mM, SKF-96365 (SKF), 30 WM, and econazole (Eco), 15 WM. Cells were then treated for
20 min with TG, 500 nM. The reaction was stopped as described in Section 2. Results are given as mean CPMTS.E.M. of three separate ex-
periments, each in duplicate. Data are signi¢cantly di¡erent as compared to TG-treated (none) (*P6 0.001) and control cells (**P6 0.001).
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TG- and PMA-induced MAPK phosphorylation in these cells
(Fig. 4A,B). The inhibitory e¡ects of DHA on TG-stimulated
MAPK activation may not be due to the inhibitory action of
this fatty acid on TG-induced SOC in£ux as prior addition of
DHA failed to curtail the TG-evoked increases in calcium in
these cells (Fig. 5a). Furthermore, addition of DHA after TG
induced an additive response on the increases in [Ca2þ]i in
these cells (Fig. 5b). The inhibitory e¡ect of DHA on
ERK1/ERK2 phosphorylation may be due to its action on
TG-induced PKC activation as this fatty acid also inhibited
PMA-stimulated MAPK activation in these cells. These ob-
servations agree well with our previous ¢ndings in which we
have shown that DHA inhibits MAPK activation by inhibit-
ing PKC in 3T3 ¢broblasts [16] and Jurkat T-cells [17,18].
TA9, econazole and SKF-96365 inhibited TG-evoked SOC
in£ux in these cells (Fig. 5c,d). Another important observation
of our study is that TG-evoked increases in [Ca2þ]i are not
curtailed by PROP, U0126 or GF109203X (Fig. 5d), indicat-
ing that activation of PLD, PKC and MAPK occurs essen-
tially downstream of calcium in£ux in Jurkat T-cells. In other
words, our observations suggest that an increase in [Ca2þ]i
stimulates the activation of these enzymes, though some in-
vestigators have suggested that TG-stimulated activation of
MAPK regulates SOC in£ux in human platelets [40].
Last, but not least, we would like to underline that Jurkat
T-cells represent a good model to study the direct action of
fatty acids in T-cell signalling as they do not possess the
enzymes of lipoxygenase and cyclooxygenase pathways that
account for lipid mediators [41,42]. The novelty of our study
lies in the fact that SOC in£ux, triggered by the depletion of
intracellular calcium stores in the presence of TG, can activate
PLD, followed by MAPK activation which is a target of
Fig. 4. TG-stimulated ERK1/ERK2 activation is inhibited by DHA.
Jurkat T-cells (5U106 cells/ml), prior to determining the ERK1/
ERK2 phosphorylation, were incubated during 6 h in RPMI 1640
medium without serum. Later on, these cells were pretreated or not
with DHA, 10 WM, or DHA-methyl ester (DHA-ME), 10 WM, and
then further treated with TG, 500 nM, or PMA, 200 nM, for 20
min. After incubation at 37‡C, cells were lysed and the detection of
phosphorylated MAPKs was performed as described in Section 2.
Fig. 5. E¡ects of TG and DHA on the increases in [Ca2þ]i. Cells (4U106/assay) were loaded with the £uorescent probe, Fura-2/AM, as de-
scribed in Section 2. The arrowheads indicate the time when the test molecules were added into the cuvette. The ¢gure shows the single traces
of observations which were reproduced independently (n=4). a and b represent successive additions of DHA, 10 WM and TG, 500 nM. c: The
cells were preincubated in the presence or not of TA9, 10 WM. d: the v increase in [Ca2þ]i induced by TG, 500 nM, in the presence or not of
various inhibitors at the following concentrations: PROP, 50 WM; U0126, 10 WM; GF109203X (GF109), 500 nM; TA9, 10 WM, econazole, 15
WM; and SKF-96365, 30 WM. Cells were preincubated for 20 min with the various inhibitors before the addition of TG. Values are meansT
S.E.M. of three independent experiments, each in triplicate. Data are signi¢cantly di¡erent as compared to TG-treated cells (*P6 0.001). NS:
insigni¢cant di¡erences as compared with TG-treated cells.
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DHA. Hence, inhibition of MAPK activation by DHA may
be one of the possible mechanisms of action of immunosup-
pression, induced by this fatty acid.
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